


Supplementary Appendix: ‘Adalimumab and infliximab impair SARS-CoV-2 antibody responses: results from a therapeutic drug monitoring study in 11422 biologic-treated patients’


Table of Contents

Supplementary Figure 1: Number of samples analysed across UK regions, by biologic therapy	2
Supplementary Figure 2: Number of samples analysed across time, by biologic therapy	3
Supplementary Figure 3: Cumulative seroprevalence of SARS-CoV-2 antibodies by month (January 2020 – September 2020)	4
Supplementary Figure 4: Regional seroprevalence of SARS-CoV-2 by NUTS1 region	5


Supplementary Figure 1: Number of samples analysed across UK regions, by biologic therapy



Supplementary Figure 2: Number of samples analysed across time, by biologic therapy



Supplementary Figure 3: Cumulative seroprevalence of SARS-CoV-2 antibodies by month (January 2020 – September 2020)



Supplementary Figure 4: Regional seroprevalence of SARS-CoV-2 by NUTS1 region

